Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: sam who wrote (4606)	6/29/1998 11:12:00 PM
From: Bhag Karamchandani	Read Replies (1) of 6136

Sam: In one of my previous postings, I argued that most start up biotechs would have close to zero valuation, if potential earnings from all future drugs were discounted, at current value, to zero. However, to then conclude that AG3340 is not hugely important to AGPH fortunes is wishful thinking. After all if AG3340's contribution to AGPH is discounted to zero why should the two AID's related collaborations be worth more since they both are less advanced than AGPH3340 towards FDA, or any other approval.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next